RNA分析市場:製品(試薬、機器、ソフトウェア、サービス)、技術(PCR、シーケンス、マイクロアレイ、RNA干渉)、用途(創薬、臨床診断)、エンドユーザー(製薬、バイオテクノロジー、CRO)、地域別 - 2028年までの世界予測RNA Analysis Market by Product (Reagents, Instruments, Software, Services), Technology (PCR, Sequencing, Microarrays, RNA Interference), Application (Drug Discovery, Clinical Diagnostics), End User (Pharma, Biotech, CROs), Region - Global Forecast to 2028 世界のRNA分析市場規模は、予測期間中に13.4%のCAGRで、2023年の53億ドルから2028年には99億ドルに達すると予測されている。トランスクリプトミクス研究の分野における進歩、治療薬の成長を支えるトランスクリプ... もっと見る
日本語のページは自動翻訳を利用し作成しています。
サマリー世界のRNA分析市場規模は、予測期間中に13.4%のCAGRで、2023年の53億ドルから2028年には99億ドルに達すると予測されている。トランスクリプトミクス研究の分野における進歩、治療薬の成長を支えるトランスクリプトミクス研究の増加によるRNA分析に使用される試薬の需要増加などの要因が、RNA分析製品・サービスの需要を促進している。"予測期間中、製品&サービス別RNA分析市場で最も高い成長率を占めたのは試薬/消耗品セグメント" 2022年、試薬/消耗品セグメントが最も高い成長率を占めた。製品・サービス市場は、試薬・消耗品、機器、サービス、ソフトウェアに区分される。治療薬、薬剤設計、遺伝子合成におけるペプチドの用途拡大や、RNA解析を伴う研究プロジェクトの増加が、RNA解析市場における同分野の優位性に寄与している。 "アジア太平洋地域はより速いペースで成長する可能性が高い" RNA分析市場は、北米、欧州、アジア太平洋地域、中南米、中東・アフリカに分けられる。2022年には、北米がRNA分析市場で圧倒的なシェアを占めた。同地域の大きなシェアは、同地域に大手企業が存在すること、新たなゲノム治療法を開発する研究活動が継続していることなど、さまざまな要因によるものである。アジア太平洋地域は、同地域におけるジェネリック医薬品に対する政府のイニシアチブの高まりや、RNA分析市場における新たな市場プレイヤーの出現などの様々な要因により、より速いペースで成長する可能性が高い。 本レポートのために実施した一次インタビューは以下のように分類できる: - 回答者別供給側70%、需要側30 - 指定(供給側)別:管理職 - 45%、CXOおよび取締役 - 30%、経営幹部 - 25 - 地域別北米:40%、欧州:25%、アジア太平洋地域:20%、中南米:10%、中東・アフリカ:5 レポート掲載企業リスト - サーモフィッシャーサイエンティフィック(米国) - F.ホフマン・ラ・ロシュ社(スイス(スイス) - バイオ・ラッド・ラボラトリーズ社(米国) - イルミナ社(米国) - ユーロフィンズ・サイエンティフィック(ルクセンブルク) - アジレント・テクノロジー(米国) - メルクKGaA(ドイツ) - ダナハーコーポレーション(米国) - プロメガ・コーポレーション(米国) - QIAGEN N.V.(ドイツ) - スタンダード・バイオツールズ(米国) - Sequentia Biotech SL(スペイン) - アコビオム(フランス) - GenXPro GmbH(ドイツ) - CD Genomics(米国) - プロメガ・コーポレーション(米国) - Lexogen GmbH(オーストリア) - セニックス・バイオサイエンス社(ドイツ) - 宝ホールディングス(日本) - バイオメリューSA(フランス) - LC Sciences LLC(米国) - オックスフォード・ナノポア・テクノロジーズ(英国) - ザイモ・リサーチ・コーポレーション(米国) - ジーンデックス(米) - パルテック・インコーポレイテッド(米) - BGIグループ(中国) 調査範囲 この調査レポートは、RNA分析市場の詳細な状況を掲載しています。製品、技術、用途、エンドユーザー、地域など、さまざまなセグメントにわたる市場規模と今後の成長可能性を推定することを目的としています。また、主要市場プレイヤーの企業プロフィールや最近の動向、主要な市場戦略とともに、詳細な競合分析も掲載しています。 レポート購入の主な利点 本レポートは、RNA分析市場全体とそのサブセグメントにおける収益数の最も近い概算値を提供することで、市場リーダー/新規参入者を支援します。また、利害関係者が競合状況をより良く理解し、より多くの洞察を得ることで、自社のビジネスをより良く位置づけ、適切な市場参入戦略を立てるのに役立ちます。本レポートは、関係者が市場の鼓動を理解し、主要な市場促進要因、阻害要因、機会、課題に関する情報を提供することを可能にします。 本レポートは、以下のポイントに関する洞察を提供します: - 主な促進要因(個別化医療に対する需要の高まり、製薬・バイオテクノロジー研究開発費と政府資金の増加、トランスクリプトミクスにおけるRNAシーケンサーの用途の増加)、阻害要因(高額な設備投資)、機会(新興市場における高い成長機会、トキシコゲノミクスにおける用途の増加、バイオマーカー探索への注目の高まり、アウトソーシングへの注目の高まり)、課題(トランスクリプトミクス研究におけるデータ管理、効果的なバイオインフォマティクスツールの欠如、熟練した専門家の不足)に関する分析。 - 製品・サービスの開発/革新:新たに発売された製品/サービスに関する詳細な洞察、RNA分析市場の技術評価。 - 市場開発:有利な市場に関する包括的な情報 - 当レポートでは、さまざまな地域のRNA分析市場を分析しています。 - 市場の多様化:新製品・サービス、未開拓の地域、最近の開発、RNA分析市場への投資に関する詳細な情報を提供します。 - 競合評価:Thermo Fisher Scientific, Inc.(米国)、F. Hoffmann-La Roche Ltd.(スイス)、Bio-Rad Laboratories, Inc.(スイス)など主要企業の市場シェア、成長戦略、製品・サービス内容を詳細に評価。(スイス)、Bio-Rad Laboratories, Inc.(米国)、Illumina, Inc.(米国)、Eurofins Scientific(ルクセンブルク)など、RNA分析市場における主要企業のシェアや成長戦略、製品・サービス内容を詳細に評価。 目次1 INTRODUCTION 281.1 STUDY OBJECTIVES 28 1.2 MARKET DEFINITION 28 1.2.1 INCLUSIONS & EXCLUSIONS 28 1.3 MARKET SCOPE 29 1.3.1 MARKETS COVERED 29 1.3.2 YEARS CONSIDERED 29 1.4 CURRENCY 30 1.5 LIMITATIONS 30 1.6 STAKEHOLDERS 30 1.7 SUMMARY OF CHANGES 31 1.7.1 RECESSION IMPACT 31 2 RESEARCH METHODOLOGY 32 2.1 RESEARCH DATA 32 FIGURE 1 RESEARCH DESIGN 32 2.1.1 SECONDARY DATA 33 2.1.2 PRIMARY DATA 34 FIGURE 2 RNA ANALYSIS MARKET: BREAKDOWN OF PRIMARIES 34 2.2 MARKET SIZE ESTIMATION 35 FIGURE 3 RNA ANALYSIS MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022) 35 FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 36 FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022 36 2.2.1 INSIGHTS FROM PRIMARIES 37 FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 37 2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, TECHNOLOGY, APPLICATION, AND END USER) 38 FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 38 2.3 GROWTH RATE ASSUMPTIONS 39 FIGURE 8 RNA ANALYSIS MARKET: CAGR PROJECTIONS, 2023–2028 39 FIGURE 9 RNA ANALYSIS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 40 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 40 FIGURE 10 DATA TRIANGULATION METHODOLOGY 41 2.5 STUDY ASSUMPTIONS 42 2.6 RISK ANALYSIS 42 2.7 IMPACT OF ECONOMIC RECESSION ON RNA ANALYSIS MARKET 42 TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2028 (% GROWTH) 43 TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 43 TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 43 3 EXECUTIVE SUMMARY 44 FIGURE 11 RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 44 FIGURE 12 RNA ANALYSIS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 45 FIGURE 13 RNA ANALYSIS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 46 FIGURE 14 RNA ANALYSIS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 47 FIGURE 15 GEOGRAPHICAL SNAPSHOT: RNA ANALYSIS MARKET 48 4 PREMIUM INSIGHTS 50 4.1 RNA ANALYSIS MARKET OVERVIEW 50 FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH 50 4.2 NORTH AMERICA: RNA ANALYSIS MARKET SHARE, BY APPLICATION & COUNTRY (2022) 51 FIGURE 17 DRUG DISCOVERY APPLICATIONS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN RNA ANALYSIS MARKET IN 2022 51 4.3 RNA ANALYSIS MARKET SHARE, BY END USER, 2022 52 FIGURE 18 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 52 4.4 RNA ANALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53 FIGURE 19 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN RNA ANALYSIS MARKET FROM 2023 TO 2028 53 4.5 RNA ANALYSIS MARKET, BY REGION (2023–2028) 54 FIGURE 20 NORTH AMERICA TO CONTINUE TO DOMINATE RNA ANALYSIS MARKET UNTIL 2028 54 4.6 RNA ANALYSIS MARKET: DEVELOPED VS. EMERGING ECONOMIES 55 FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 55 5 MARKET OVERVIEW 56 5.1 INTRODUCTION 56 5.2 MARKET DYNAMICS 56 FIGURE 22 MARKET DYNAMICS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56 TABLE 4 RNA ANALYSIS MARKET: IMPACT ANALYSIS 57 5.2.1 DRIVERS 57 5.2.1.1 Growing demand for personalized medicine 57 FIGURE 23 PERSONALIZED MEDICINES APPROVED BY FDA, 2015–2022 58 5.2.1.2 Rising pharmaceutical and biotechnology R&D expenditure and government funding 59 FIGURE 24 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026 60 5.2.1.3 Increasing applications of RNA sequencing in transcriptomics 60 5.2.2 RESTRAINTS 61 5.2.2.1 High capital investments 61 5.2.3 OPPORTUNITIES 61 5.2.3.1 High growth opportunities in emerging markets 61 5.2.3.2 Increasing applications in toxicogenomics 62 5.2.3.3 Increasing focus on biomarker discovery 63 5.2.3.4 Rising focus on outsourcing 63 5.2.4 CHALLENGES 63 5.2.4.1 Data management in transcriptomics research 63 5.2.4.2 Lack of effective bioinformatics tools 64 5.2.4.3 Dearth of skilled professionals 64 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 65 5.4 VALUE CHAIN ANALYSIS 66 FIGURE 25 VALUE CHAIN ANALYSIS OF RNA ANALYSIS MARKET: RESEARCH AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE 66 5.5 SUPPLY CHAIN ANALYSIS 67 FIGURE 26 RNA ANALYSIS MARKET: SUPPLY CHAIN ANALYSIS 68 5.6 ECOSYSTEM ANALYSIS 68 TABLE 5 SUPPLY CHAIN ECOSYSTEM 69 5.7 PATENT ANALYSIS 70 FIGURE 27 PATENT APPLICATIONS FOR RNA ANALYSIS MARKET, JUNE 2012–JUNE 2023 70 5.8 LIST OF MAJOR PATENTS 71 5.9 TECHNOLOGY ANALYSIS 72 TABLE 6 COMPARISON OF MODERN RNA ANALYSIS METHODS 73 5.10 PORTER’S FIVE FORCES ANALYSIS 73 TABLE 7 RNA ANALYSIS MARKET: PORTER’S FIVE FORCES ANALYSIS 73 5.10.1 THREAT OF NEW ENTRANTS 74 5.10.2 THREAT OF SUBSTITUTES 74 5.10.3 BARGAINING POWER OF SUPPLIERS 74 5.10.4 BARGAINING POWER OF BUYERS 74 5.10.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS 74 5.11 REGULATORY ANALYSIS 75 5.11.1 REGULATIONS FOR RNA ANALYSIS PRODUCTS 75 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76 TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77 5.12 KEY CONFERENCES AND EVENTS IN 2023 78 TABLE 11 RNA ANALYSIS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023 78 5.13 KEY STAKEHOLDERS & BUYING CRITERIA 79 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 79 FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RNA ANALYSIS PRODUCTS 79 5.13.2 BUYING CRITERIA 80 FIGURE 29 KEY BUYING CRITERIA FOR END USERS 80 6 RNA ANALYSIS MARKET, BY PRODUCT & SERVICE 81 6.1 INTRODUCTION 82 TABLE 12 RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 82 6.2 REAGENTS/CONSUMABLES 82 6.2.1 REAGENTS/CONSUMABLES TO DOMINATE MARKET DURING FORECAST PERIOD 82 TABLE 13 RNA ANALYSIS REAGENTS/CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION) 84 TABLE 14 NORTH AMERICA: RNA ANALYSIS REAGENTS/CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84 TABLE 15 EUROPE: RNA ANALYSIS REAGENTS/CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85 TABLE 16 ASIA PACIFIC: RNA ANALYSIS REAGENTS/CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85 6.3 INSTRUMENTS 86 6.3.1 GROWING NEED FOR ACCURATE ANALYSIS TO DRIVE ADOPTION OF AUTOMATED INSTRUMENTS 86 TABLE 17 RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87 TABLE 18 NORTH AMERICA: RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87 TABLE 19 EUROPE: RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88 TABLE 20 ASIA PACIFIC: RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88 6.4 SOFTWARE 89 6.4.1 GROWING NEED FOR DATA MANAGEMENT AND QUALITY ENHANCEMENTS TO DRIVE DEMAND FOR SOFTWARE SOLUTIONS 89 TABLE 21 RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90 TABLE 22 NORTH AMERICA: RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90 TABLE 23 EUROPE: RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91 TABLE 24 ASIA PACIFIC: RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91 6.5 SERVICES 92 6.5.1 INCREASING OUTSOURCING OF SERVICES TO PROPEL MARKET GROWTH 92 TABLE 25 RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93 TABLE 26 NORTH AMERICA: RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93 TABLE 27 EUROPE: RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94 TABLE 28 ASIA PACIFIC: RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94 7 RNA ANALYSIS MARKET, BY TECHNOLOGY 95 7.1 INTRODUCTION 96 TABLE 29 RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 96 7.2 POLYMERASE CHAIN REACTION 96 7.2.1 ABILITY OF REAL-TIME PCR TO AID IN QUANTIFICATION OF LOW-COPY TRANSCRIPTS TO BOOST DEMAND 96 TABLE 30 RNA ANALYSIS MARKET FOR PCR TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION) 97 TABLE 31 NORTH AMERICA: RNA ANALYSIS MARKET FOR PCR TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 98 TABLE 32 EUROPE: RNA ANALYSIS MARKET FOR PCR TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 98 TABLE 33 ASIA PACIFIC: RNA ANALYSIS MARKET FOR PCR TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 99 7.3 SEQUENCING 99 7.3.1 ADVANCES IN NGS MULTIPLEXING CAPABILITIES TO AID MARKET GROWTH 99 TABLE 34 RNA ANALYSIS MARKET FOR SEQUENCING TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION) 101 TABLE 35 NORTH AMERICA: RNA ANALYSIS MARKET FOR SEQUENCING TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 101 TABLE 36 EUROPE: RNA ANALYSIS MARKET FOR SEQUENCING TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 102 TABLE 37 ASIA PACIFIC: RNA ANALYSIS MARKET FOR SEQUENCING TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 102 7.4 MICROARRAYS 103 7.4.1 WIDE ADOPTION OF MICROARRAYS IN CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH 103 TABLE 38 RNA ANALYSIS MARKET FOR MICROARRAY TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION) 104 TABLE 39 NORTH AMERICA: RNA ANALYSIS MARKET FOR MICROARRAY TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 104 TABLE 40 EUROPE: RNA ANALYSIS MARKET FOR MICROARRAY TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 105 TABLE 41 ASIA PACIFIC: RNA ANALYSIS MARKET FOR MICROARRAY TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 105 7.5 RNA INTERFERENCE 106 7.5.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT ADOPTION OF TECHNIQUE FOR DIAGNOSTICS AND THERAPEUTICS 106 TABLE 42 RNA ANALYSIS MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION) 107 TABLE 43 NORTH AMERICA: RNA ANALYSIS MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 107 TABLE 44 EUROPE: RNA ANALYSIS MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 108 TABLE 45 ASIA PACIFIC: RNA ANALYSIS MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 108 8 RNA ANALYSIS MARKET, BY APPLICATION 109 8.1 INTRODUCTION 110 TABLE 46 RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110 8.2 DRUG DISCOVERY 110 8.2.1 GROWING POPULARITY OF TARGETED SEQUENCING-BASED APPROACHES IN DRUG DISCOVERY TO BOOST MARKET 110 TABLE 47 RNA ANALYSIS MARKET FOR DRUG DISCOVERY, BY REGION, 2021–2028 (USD MILLION) 111 TABLE 48 NORTH AMERICA: RNA ANALYSIS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION) 112 TABLE 49 EUROPE: RNA ANALYSIS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION) 112 TABLE 50 ASIA PACIFIC: RNA ANALYSIS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION) 113 8.3 CLINICAL DIAGNOSTICS 113 8.3.1 GROWING ADOPTION OF TRANSCRIPTOMICS FOR LARGE-SCALE GENE EXPRESSION PROFILING OF ONCOLOGICAL DISORDERS TO FUEL GROWTH 113 TABLE 51 RNA ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 115 TABLE 52 NORTH AMERICA: RNA ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 115 TABLE 53 EUROPE: RNA ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 116 TABLE 54 ASIA PACIFIC: RNA ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 116 8.4 TOXICOGENOMICS 117 8.4.1 GROWING FOCUS ON ADR STUDIES TO DRIVE ADOPTION OF TRANSCRIPTOMICS FOR SYSTEMIC TOXICOLOGY 117 TABLE 55 RNA ANALYSIS MARKET FOR TOXICOGENOMICS, BY REGION, 2021–2028 (USD MILLION) 118 TABLE 56 NORTH AMERICA: RNA ANALYSIS MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 118 TABLE 57 EUROPE: RNA ANALYSIS MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 119 TABLE 58 ASIA PACIFIC: RNA ANALYSIS MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 119 8.5 COMPARATIVE TRANSCRIPTOMICS 120 8.5.1 WIDE ADOPTION OF TRANSCRIPTIONAL PROFILES TO STUDY EVOLUTION AMONG SPECIES TO PROPEL GROWTH 120 TABLE 59 RNA ANALYSIS MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY REGION, 2021–2028 (USD MILLION) 121 TABLE 60 NORTH AMERICA: RNA ANALYSIS MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 121 TABLE 61 EUROPE: RNA ANALYSIS MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 122 TABLE 62 ASIA PACIFIC: RNA ANALYSIS MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 122 9 RNA ANALYSIS MARKET, BY END USER 123 9.1 INTRODUCTION 124 TABLE 63 RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 124 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 124 9.2.1 INCREASING INVESTMENTS FOR ONCOLOGY THERAPEUTICS TO DRIVE USE OF OMICS TECHNOLOGIES IN PHARMA & BIOTECH COMPANIES 124 TABLE 64 RNA ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 125 TABLE 65 NORTH AMERICA: RNA ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 126 TABLE 66 EUROPE: RNA ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 126 TABLE 67 ASIA PACIFIC: RNA ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 127 9.3 HOSPITALS & DIAGNOSTIC CENTERS 127 9.3.1 USE OF WHOLE-BLOOD TRANSCRIPTOME PROFILES FOR DISEASE DIAGNOSTICS TO FAVOR MARKET GROWTH 127 TABLE 68 RNA ANALYSIS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2021–2028 (USD MILLION) 128 TABLE 69 NORTH AMERICA: RNA ANALYSIS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 128 TABLE 70 EUROPE: RNA ANALYSIS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 129 TABLE 71 ASIA PACIFIC: RNA ANALYSIS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 129 9.4 ACADEMIC & RESEARCH INSTITUTES 130 9.4.1 GROWING GOVERNMENT INVESTMENTS TO PROPEL MARKET GROWTH 130 TABLE 72 RNA ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 130 TABLE 73 NORTH AMERICA: RNA ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 131 TABLE 74 EUROPE: RNA ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 131 TABLE 75 ASIA PACIFIC: RNA ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 132 9.5 CONTRACT RESEARCH ORGANIZATIONS 132 9.5.1 GROWING OUTSOURCING OF SERVICES BY PHARMACEUTICAL COMPANIES FOR FASTER DRUG DISCOVERY TO AID MARKET GROWTH 132 TABLE 76 RNA ANALYSIS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 133 TABLE 77 NORTH AMERICA: RNA ANALYSIS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 133 TABLE 78 EUROPE: RNA ANALYSIS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 134 TABLE 79 ASIA PACIFIC: RNA ANALYSIS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 134 10 RNA ANALYSIS MARKET, BY REGION 135 10.1 INTRODUCTION 136 TABLE 80 RNA ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 136 10.2 NORTH AMERICA 137 FIGURE 30 NORTH AMERICA: RNA ANALYSIS MARKET SNAPSHOT 138 TABLE 81 NORTH AMERICA: RNA ANALYSIS MARKET, BY COUNTRY, 2021–2028(USD MILLION) 139 TABLE 82 NORTH AMERICA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 139 TABLE 83 NORTH AMERICA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 140 TABLE 84 NORTH AMERICA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 140 TABLE 85 NORTH AMERICA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 141 10.2.1 US 141 10.2.1.1 US to dominate North American RNA analysis market during forecast period 141 TABLE 86 US: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 142 TABLE 87 US: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143 TABLE 88 US: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 143 TABLE 89 US: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 144 10.2.2 CANADA 144 10.2.2.1 Improving funding and infrastructure for omics-based research to support market growth 144 TABLE 90 CANADA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 145 TABLE 91 CANADA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 146 TABLE 92 CANADA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 146 TABLE 93 CANADA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 147 10.2.3 NORTH AMERICA: RECESSION IMPACT 147 10.3 EUROPE 147 TABLE 94 EUROPE: RNA ANALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148 TABLE 95 EUROPE: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 149 TABLE 96 EUROPE: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 149 TABLE 97 EUROPE: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 150 TABLE 98 EUROPE: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 150 10.3.1 GERMANY 151 10.3.1.1 Germany to hold largest share of European RNA analysis market during forecast period 151 TABLE 99 GERMANY: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 152 TABLE 100 GERMANY: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 152 TABLE 101 GERMANY: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 153 TABLE 102 GERMANY: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 153 10.3.2 UK 154 10.3.2.1 Rising public and private funding for research to drive market growth 154 TABLE 103 UK: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 154 TABLE 104 UK: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 155 TABLE 105 UK: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 155 TABLE 106 UK: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 156 10.3.3 FRANCE 156 10.3.3.1 Increasing government support for omics-based research to support market growth 156 TABLE 107 FRANCE: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 157 TABLE 108 FRANCE: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 157 TABLE 109 FRANCE: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 158 TABLE 110 FRANCE: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 158 10.3.4 ITALY 159 10.3.4.1 Improving R&D expenditure and disease diagnostics to boost market 159 TABLE 111 ITALY: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 159 TABLE 112 ITALY: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 160 TABLE 113 ITALY: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 160 TABLE 114 ITALY: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 161 10.3.5 SPAIN 161 10.3.5.1 Increasing collaborations for enhancing research to support market growth 161 TABLE 115 SPAIN: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 162 TABLE 116 SPAIN: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 162 TABLE 117 SPAIN: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 163 TABLE 118 SPAIN: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 163 10.3.6 SWITZERLAND 164 10.3.6.1 Well-established pharmaceutical industry to drive market growth 164 TABLE 119 SWITZERLAND: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 164 TABLE 120 SWITZERLAND: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 165 TABLE 121 SWITZERLAND: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 165 TABLE 122 SWITZERLAND: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 166 10.3.7 REST OF EUROPE 166 TABLE 123 REST OF EUROPE: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 167 TABLE 124 REST OF EUROPE: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 167 TABLE 125 REST OF EUROPE: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 168 TABLE 126 REST OF EUROPE: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 168 10.4 EUROPE: RECESSION IMPACT 169 10.5 ASIA PACIFIC 169 FIGURE 31 ASIA PACIFIC: RNA ANALYSIS MARKET SNAPSHOT 170 TABLE 127 ASIA PACIFIC: RNA ANALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 171 TABLE 128 ASIA PACIFIC: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 171 TABLE 129 ASIA PACIFIC: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 172 TABLE 130 ASIA PACIFIC: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 172 TABLE 131 ASIA PACIFIC: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 173 10.5.1 CHINA 173 10.5.1.1 China to be fastest-growing market in Asia Pacific during forecast period 173 TABLE 132 CHINA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 174 TABLE 133 CHINA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 175 TABLE 134 CHINA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 175 TABLE 135 CHINA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 176 10.5.2 JAPAN 176 10.5.2.1 Early adoption of technologically advanced products to drive market growth 176 TABLE 136 JAPAN: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 177 TABLE 137 JAPAN: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 177 TABLE 138 JAPAN: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 178 TABLE 139 JAPAN: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 178 10.5.3 INDIA 179 10.5.3.1 Increasing pharmaceutical R&D spending and government funding for research to drive market growth 179 TABLE 140 INDIA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 180 TABLE 141 INDIA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 180 TABLE 142 INDIA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 181 TABLE 143 INDIA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 181 10.5.4 REST OF ASIA PACIFIC 182 TABLE 144 REST OF ASIA PACIFIC: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 183 TABLE 145 REST OF ASIA PACIFIC: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 183 TABLE 146 REST OF ASIA PACIFIC: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 184 TABLE 147 REST OF ASIA PACIFIC: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 184 10.6 ASIA PACIFIC: RECESSION IMPACT 185 10.7 LATIN AMERICA 185 10.7.1 GROWTH IN PHARMACEUTICAL INDUSTRY IN MEXICO TO SUPPORT MARKET GROWTH 185 TABLE 148 LATIN AMERICA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 186 TABLE 149 LATIN AMERICA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 186 TABLE 150 LATIN AMERICA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 187 TABLE 151 LATIN AMERICA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 187 10.8 LATIN AMERICA: RECESSION IMPACT 188 10.9 MIDDLE EAST & AFRICA 188 10.9.1 IMPROVING FOCUS ON PRECISION MEDICINE AND DISEASE GENETICS TO DRIVE MARKET GROWTH 188 TABLE 152 MIDDLE EAST & AFRICA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 189 TABLE 153 MIDDLE EAST & AFRICA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 189 TABLE 154 MIDDLE EAST & AFRICA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 190 TABLE 155 MIDDLE EAST & AFRICA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 190 10.10 MIDDLE EAST & AFRICA: RECESSION IMPACT 191 11 COMPETITIVE LANDSCAPE 192 11.1 INTRODUCTION 192 11.2 STRATEGIES ADOPTED BY KEY PLAYERS 192 FIGURE 32 RNA ANALYSIS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 193 11.3 REVENUE SHARE ANALYSIS 194 FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022 194 11.4 MARKET SHARE ANALYSIS 194 FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022 195 TABLE 156 RNA ANALYSIS MARKET: DEGREE OF COMPETITION 195 11.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS 196 FIGURE 35 RNA ANALYSIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 197 11.5.1 STARS 197 11.5.2 EMERGING LEADERS 197 11.5.3 PERVASIVE PLAYERS 198 11.5.4 PARTICIPANTS 198 11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 198 11.6.1 COMPANY PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES) 198 TABLE 157 COMPANY PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN RNA ANALYSIS MARKET 198 11.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES) 199 TABLE 158 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN RNA ANALYSIS MARKET 199 11.7 COMPANY EVALUATION QUADRANT: STARTUPS/SMES 200 FIGURE 36 RNA ANALYSIS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/ SMES, 2022 200 11.7.1 PROGRESSIVE COMPANIES 201 11.7.2 STARTING BLOCKS 201 11.7.3 RESPONSIVE COMPANIES 201 11.7.4 DYNAMIC COMPANIES 201 11.8 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 202 TABLE 159 RNA ANALYSIS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 202 TABLE 160 RNA ANALYSIS MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 203 11.9 COMPETITIVE SCENARIO AND TRENDS 203 11.9.1 PRODUCT LAUNCHES 203 TABLE 161 RNA ANALYSIS MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2020–JUNE 2023 203 11.9.2 DEALS 204 TABLE 162 RNA ANALYSIS MARKET: DEALS, JANUARY 2020–JUNE 2023 204 11.9.3 OTHER DEVELOPMENTS 205 TABLE 163 RNA ANALYSIS MARKET: OTHER DEVELOPMENTS, JANUARY 2020–JUNE 2023 205 12 COMPANY PROFILES 206 12.1 KEY PLAYERS 206 (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 12.1.1 THERMO FISHER SCIENTIFIC INC. 206 TABLE 164 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 206 FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 207 12.1.2 F. HOFFMANN-LA ROCHE LTD. 212 TABLE 165 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 212 FIGURE 38 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 213 12.1.3 BIO-RAD LABORATORIES, INC. 216 TABLE 166 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 216 FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 217 12.1.4 ILLUMINA, INC. 220 TABLE 167 ILLUMINA, INC.: COMPANY OVERVIEW 220 FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT (2022) 221 12.1.5 EUROFINS SCIENTIFIC 224 TABLE 168 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 224 FIGURE 41 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022) 224 12.1.6 AGILENT TECHNOLOGIES, INC. 227 TABLE 169 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 227 FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022) 228 12.1.7 CD GENOMICS 230 TABLE 170 CD GENOMICS: COMPANY OVERVIEW 230 12.1.8 PROMEGA CORPORATION 232 TABLE 171 PROMEGA CORPORATION: COMPANY OVERVIEW 232 12.1.9 QIAGEN N.V. 234 TABLE 172 QIAGEN N.V.: COMPANY OVERVIEW 234 FIGURE 43 QIAGEN N.V.: COMPANY SNAPSHOT (2022) 235 12.1.10 DANAHER CORPORATION 237 TABLE 173 DANAHER CORPORATION: COMPANY OVERVIEW 237 FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 238 12.1.11 MERCK KGAA 240 TABLE 174 MERCK KGAA: BUSINESS OVERVIEW 240 FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2022) 241 12.1.12 STANDARD BIOTOOLS INC. (FLUIDIGM CORPORATION) 243 TABLE 175 STANDARD BIOTOOLS INC.: BUSINESS OVERVIEW 243 FIGURE 46 STANDARD BIOTOOLS INC.: COMPANY SNAPSHOT (2022) 243 12.1.13 SEQUENTIA BIOTECH SL 245 TABLE 176 SEQUENTIA BIOTECH SL: BUSINESS OVERVIEW 245 12.1.14 ACOBIOM 246 TABLE 177 ACOBIOM: BUSINESS OVERVIEW 246 12.1.15 GENXPRO GMBH 247 TABLE 178 GENXPRO GMBH: BUSINESS OVERVIEW 247 12.2 OTHER PLAYERS 248 12.2.1 LEXOGEN GMBH 248 12.2.2 CENIX BIOSCIENCE GMBH 249 12.2.3 TAKARA HOLDINGS INC. 250 12.2.4 BIOMÉRIEUX SA 251 12.2.5 LC SCIENCES LLC 252 12.2.6 OXFORD NANOPORE TECHNOLOGIES 253 12.2.7 ZYMO RESEARCH CORPORATION 254 12.2.8 GENEDX 255 12.2.9 PARTEK INCORPORATED 255 12.2.10 BGI GROUP 256 *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 13 APPENDIX 257 13.1 DISCUSSION GUIDE 257 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 260 13.3 CUSTOMIZATION OPTIONS 262 13.4 RELATED REPORTS 262 13.5 AUTHOR DETAILS 263
SummaryThe global RNA analysis market size is projected to reach USD 9.9 billion by 2028 from 5.3 billion in 2023, at a CAGR of 13.4% during the forecast period. Factors such as the advancements in the field of transcriptomics studies, and the rising demand for reagents used in RNA analysis due to increased transcriptomics studies supporting the growth of therapeutics are driving the demand for RNA analysis products & services. Table of Contents1 INTRODUCTION 281.1 STUDY OBJECTIVES 28 1.2 MARKET DEFINITION 28 1.2.1 INCLUSIONS & EXCLUSIONS 28 1.3 MARKET SCOPE 29 1.3.1 MARKETS COVERED 29 1.3.2 YEARS CONSIDERED 29 1.4 CURRENCY 30 1.5 LIMITATIONS 30 1.6 STAKEHOLDERS 30 1.7 SUMMARY OF CHANGES 31 1.7.1 RECESSION IMPACT 31 2 RESEARCH METHODOLOGY 32 2.1 RESEARCH DATA 32 FIGURE 1 RESEARCH DESIGN 32 2.1.1 SECONDARY DATA 33 2.1.2 PRIMARY DATA 34 FIGURE 2 RNA ANALYSIS MARKET: BREAKDOWN OF PRIMARIES 34 2.2 MARKET SIZE ESTIMATION 35 FIGURE 3 RNA ANALYSIS MARKET SIZE ESTIMATION: SUPPLY-SIDE ANALYSIS (2022) 35 FIGURE 4 MARKET SIZE ESTIMATION: APPROACH 1 (REVENUE SHARE ANALYSIS), 2022 36 FIGURE 5 ILLUSTRATIVE EXAMPLE OF THERMO FISHER SCIENTIFIC, INC.: REVENUE SHARE ANALYSIS, 2022 36 2.2.1 INSIGHTS FROM PRIMARIES 37 FIGURE 6 MARKET VALIDATION FROM PRIMARY EXPERTS 37 2.2.2 SEGMENT ASSESSMENT (BY PRODUCT, TECHNOLOGY, APPLICATION, AND END USER) 38 FIGURE 7 MARKET SIZE ESTIMATION METHODOLOGY: TOP-DOWN APPROACH 38 2.3 GROWTH RATE ASSUMPTIONS 39 FIGURE 8 RNA ANALYSIS MARKET: CAGR PROJECTIONS, 2023–2028 39 FIGURE 9 RNA ANALYSIS MARKET: GROWTH ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 40 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 40 FIGURE 10 DATA TRIANGULATION METHODOLOGY 41 2.5 STUDY ASSUMPTIONS 42 2.6 RISK ANALYSIS 42 2.7 IMPACT OF ECONOMIC RECESSION ON RNA ANALYSIS MARKET 42 TABLE 1 GLOBAL INFLATION RATE PROJECTIONS, 2024–2028 (% GROWTH) 43 TABLE 2 US HEALTH EXPENDITURE, 2019–2022 (USD MILLION) 43 TABLE 3 US HEALTH EXPENDITURE, 2023–2027 (USD MILLION) 43 3 EXECUTIVE SUMMARY 44 FIGURE 11 RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2023 VS. 2028 (USD MILLION) 44 FIGURE 12 RNA ANALYSIS MARKET, BY TECHNOLOGY, 2023 VS. 2028 (USD MILLION) 45 FIGURE 13 RNA ANALYSIS MARKET, BY APPLICATION, 2023 VS. 2028 (USD MILLION) 46 FIGURE 14 RNA ANALYSIS MARKET, BY END USER, 2023 VS. 2028 (USD MILLION) 47 FIGURE 15 GEOGRAPHICAL SNAPSHOT: RNA ANALYSIS MARKET 48 4 PREMIUM INSIGHTS 50 4.1 RNA ANALYSIS MARKET OVERVIEW 50 FIGURE 16 RISING INVESTMENTS IN PHARMACEUTICAL R&D TO DRIVE MARKET GROWTH 50 4.2 NORTH AMERICA: RNA ANALYSIS MARKET SHARE, BY APPLICATION & COUNTRY (2022) 51 FIGURE 17 DRUG DISCOVERY APPLICATIONS ACCOUNTED FOR LARGEST SHARE OF NORTH AMERICAN RNA ANALYSIS MARKET IN 2022 51 4.3 RNA ANALYSIS MARKET SHARE, BY END USER, 2022 52 FIGURE 18 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES ACCOUNTED FOR LARGEST MARKET SHARE IN 2022 52 4.4 RNA ANALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 53 FIGURE 19 ASIA PACIFIC TO REGISTER HIGHEST GROWTH RATE IN RNA ANALYSIS MARKET FROM 2023 TO 2028 53 4.5 RNA ANALYSIS MARKET, BY REGION (2023–2028) 54 FIGURE 20 NORTH AMERICA TO CONTINUE TO DOMINATE RNA ANALYSIS MARKET UNTIL 2028 54 4.6 RNA ANALYSIS MARKET: DEVELOPED VS. EMERGING ECONOMIES 55 FIGURE 21 EMERGING ECONOMIES TO REGISTER HIGHER GROWTH RATES DURING FORECAST PERIOD 55 5 MARKET OVERVIEW 56 5.1 INTRODUCTION 56 5.2 MARKET DYNAMICS 56 FIGURE 22 MARKET DYNAMICS: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 56 TABLE 4 RNA ANALYSIS MARKET: IMPACT ANALYSIS 57 5.2.1 DRIVERS 57 5.2.1.1 Growing demand for personalized medicine 57 FIGURE 23 PERSONALIZED MEDICINES APPROVED BY FDA, 2015–2022 58 5.2.1.2 Rising pharmaceutical and biotechnology R&D expenditure and government funding 59 FIGURE 24 INCREASE IN GLOBAL PHARMACEUTICAL R&D SPENDING, 2012–2026 60 5.2.1.3 Increasing applications of RNA sequencing in transcriptomics 60 5.2.2 RESTRAINTS 61 5.2.2.1 High capital investments 61 5.2.3 OPPORTUNITIES 61 5.2.3.1 High growth opportunities in emerging markets 61 5.2.3.2 Increasing applications in toxicogenomics 62 5.2.3.3 Increasing focus on biomarker discovery 63 5.2.3.4 Rising focus on outsourcing 63 5.2.4 CHALLENGES 63 5.2.4.1 Data management in transcriptomics research 63 5.2.4.2 Lack of effective bioinformatics tools 64 5.2.4.3 Dearth of skilled professionals 64 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES 65 5.4 VALUE CHAIN ANALYSIS 66 FIGURE 25 VALUE CHAIN ANALYSIS OF RNA ANALYSIS MARKET: RESEARCH AND MANUFACTURING PHASES CONTRIBUTE MAXIMUM VALUE 66 5.5 SUPPLY CHAIN ANALYSIS 67 FIGURE 26 RNA ANALYSIS MARKET: SUPPLY CHAIN ANALYSIS 68 5.6 ECOSYSTEM ANALYSIS 68 TABLE 5 SUPPLY CHAIN ECOSYSTEM 69 5.7 PATENT ANALYSIS 70 FIGURE 27 PATENT APPLICATIONS FOR RNA ANALYSIS MARKET, JUNE 2012–JUNE 2023 70 5.8 LIST OF MAJOR PATENTS 71 5.9 TECHNOLOGY ANALYSIS 72 TABLE 6 COMPARISON OF MODERN RNA ANALYSIS METHODS 73 5.10 PORTER’S FIVE FORCES ANALYSIS 73 TABLE 7 RNA ANALYSIS MARKET: PORTER’S FIVE FORCES ANALYSIS 73 5.10.1 THREAT OF NEW ENTRANTS 74 5.10.2 THREAT OF SUBSTITUTES 74 5.10.3 BARGAINING POWER OF SUPPLIERS 74 5.10.4 BARGAINING POWER OF BUYERS 74 5.10.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS 74 5.11 REGULATORY ANALYSIS 75 5.11.1 REGULATIONS FOR RNA ANALYSIS PRODUCTS 75 5.11.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 TABLE 8 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 75 TABLE 9 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 76 TABLE 10 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 77 5.12 KEY CONFERENCES AND EVENTS IN 2023 78 TABLE 11 RNA ANALYSIS MARKET: DETAILED LIST OF CONFERENCES AND EVENTS IN 2023 78 5.13 KEY STAKEHOLDERS & BUYING CRITERIA 79 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 79 FIGURE 28 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS OF RNA ANALYSIS PRODUCTS 79 5.13.2 BUYING CRITERIA 80 FIGURE 29 KEY BUYING CRITERIA FOR END USERS 80 6 RNA ANALYSIS MARKET, BY PRODUCT & SERVICE 81 6.1 INTRODUCTION 82 TABLE 12 RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 82 6.2 REAGENTS/CONSUMABLES 82 6.2.1 REAGENTS/CONSUMABLES TO DOMINATE MARKET DURING FORECAST PERIOD 82 TABLE 13 RNA ANALYSIS REAGENTS/CONSUMABLES MARKET, BY REGION, 2021–2028 (USD MILLION) 84 TABLE 14 NORTH AMERICA: RNA ANALYSIS REAGENTS/CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 84 TABLE 15 EUROPE: RNA ANALYSIS REAGENTS/CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85 TABLE 16 ASIA PACIFIC: RNA ANALYSIS REAGENTS/CONSUMABLES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 85 6.3 INSTRUMENTS 86 6.3.1 GROWING NEED FOR ACCURATE ANALYSIS TO DRIVE ADOPTION OF AUTOMATED INSTRUMENTS 86 TABLE 17 RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87 TABLE 18 NORTH AMERICA: RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 87 TABLE 19 EUROPE: RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88 TABLE 20 ASIA PACIFIC: RNA ANALYSIS INSTRUMENTS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 88 6.4 SOFTWARE 89 6.4.1 GROWING NEED FOR DATA MANAGEMENT AND QUALITY ENHANCEMENTS TO DRIVE DEMAND FOR SOFTWARE SOLUTIONS 89 TABLE 21 RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90 TABLE 22 NORTH AMERICA: RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 90 TABLE 23 EUROPE: RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91 TABLE 24 ASIA PACIFIC: RNA ANALYSIS SOFTWARE MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 91 6.5 SERVICES 92 6.5.1 INCREASING OUTSOURCING OF SERVICES TO PROPEL MARKET GROWTH 92 TABLE 25 RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93 TABLE 26 NORTH AMERICA: RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 93 TABLE 27 EUROPE: RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94 TABLE 28 ASIA PACIFIC: RNA ANALYSIS SERVICES MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 94 7 RNA ANALYSIS MARKET, BY TECHNOLOGY 95 7.1 INTRODUCTION 96 TABLE 29 RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 96 7.2 POLYMERASE CHAIN REACTION 96 7.2.1 ABILITY OF REAL-TIME PCR TO AID IN QUANTIFICATION OF LOW-COPY TRANSCRIPTS TO BOOST DEMAND 96 TABLE 30 RNA ANALYSIS MARKET FOR PCR TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION) 97 TABLE 31 NORTH AMERICA: RNA ANALYSIS MARKET FOR PCR TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 98 TABLE 32 EUROPE: RNA ANALYSIS MARKET FOR PCR TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 98 TABLE 33 ASIA PACIFIC: RNA ANALYSIS MARKET FOR PCR TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 99 7.3 SEQUENCING 99 7.3.1 ADVANCES IN NGS MULTIPLEXING CAPABILITIES TO AID MARKET GROWTH 99 TABLE 34 RNA ANALYSIS MARKET FOR SEQUENCING TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION) 101 TABLE 35 NORTH AMERICA: RNA ANALYSIS MARKET FOR SEQUENCING TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 101 TABLE 36 EUROPE: RNA ANALYSIS MARKET FOR SEQUENCING TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 102 TABLE 37 ASIA PACIFIC: RNA ANALYSIS MARKET FOR SEQUENCING TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 102 7.4 MICROARRAYS 103 7.4.1 WIDE ADOPTION OF MICROARRAYS IN CLINICAL DIAGNOSTICS TO SUPPORT MARKET GROWTH 103 TABLE 38 RNA ANALYSIS MARKET FOR MICROARRAY TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION) 104 TABLE 39 NORTH AMERICA: RNA ANALYSIS MARKET FOR MICROARRAY TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 104 TABLE 40 EUROPE: RNA ANALYSIS MARKET FOR MICROARRAY TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 105 TABLE 41 ASIA PACIFIC: RNA ANALYSIS MARKET FOR MICROARRAY TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 105 7.5 RNA INTERFERENCE 106 7.5.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT ADOPTION OF TECHNIQUE FOR DIAGNOSTICS AND THERAPEUTICS 106 TABLE 42 RNA ANALYSIS MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY REGION, 2021–2028 (USD MILLION) 107 TABLE 43 NORTH AMERICA: RNA ANALYSIS MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 107 TABLE 44 EUROPE: RNA ANALYSIS MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 108 TABLE 45 ASIA PACIFIC: RNA ANALYSIS MARKET FOR RNA INTERFERENCE TECHNOLOGY, BY COUNTRY, 2021–2028 (USD MILLION) 108 8 RNA ANALYSIS MARKET, BY APPLICATION 109 8.1 INTRODUCTION 110 TABLE 46 RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 110 8.2 DRUG DISCOVERY 110 8.2.1 GROWING POPULARITY OF TARGETED SEQUENCING-BASED APPROACHES IN DRUG DISCOVERY TO BOOST MARKET 110 TABLE 47 RNA ANALYSIS MARKET FOR DRUG DISCOVERY, BY REGION, 2021–2028 (USD MILLION) 111 TABLE 48 NORTH AMERICA: RNA ANALYSIS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION) 112 TABLE 49 EUROPE: RNA ANALYSIS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION) 112 TABLE 50 ASIA PACIFIC: RNA ANALYSIS MARKET FOR DRUG DISCOVERY, BY COUNTRY, 2021–2028 (USD MILLION) 113 8.3 CLINICAL DIAGNOSTICS 113 8.3.1 GROWING ADOPTION OF TRANSCRIPTOMICS FOR LARGE-SCALE GENE EXPRESSION PROFILING OF ONCOLOGICAL DISORDERS TO FUEL GROWTH 113 TABLE 51 RNA ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY REGION, 2021–2028 (USD MILLION) 115 TABLE 52 NORTH AMERICA: RNA ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 115 TABLE 53 EUROPE: RNA ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 116 TABLE 54 ASIA PACIFIC: RNA ANALYSIS MARKET FOR CLINICAL DIAGNOSTICS, BY COUNTRY, 2021–2028 (USD MILLION) 116 8.4 TOXICOGENOMICS 117 8.4.1 GROWING FOCUS ON ADR STUDIES TO DRIVE ADOPTION OF TRANSCRIPTOMICS FOR SYSTEMIC TOXICOLOGY 117 TABLE 55 RNA ANALYSIS MARKET FOR TOXICOGENOMICS, BY REGION, 2021–2028 (USD MILLION) 118 TABLE 56 NORTH AMERICA: RNA ANALYSIS MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 118 TABLE 57 EUROPE: RNA ANALYSIS MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 119 TABLE 58 ASIA PACIFIC: RNA ANALYSIS MARKET FOR TOXICOGENOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 119 8.5 COMPARATIVE TRANSCRIPTOMICS 120 8.5.1 WIDE ADOPTION OF TRANSCRIPTIONAL PROFILES TO STUDY EVOLUTION AMONG SPECIES TO PROPEL GROWTH 120 TABLE 59 RNA ANALYSIS MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY REGION, 2021–2028 (USD MILLION) 121 TABLE 60 NORTH AMERICA: RNA ANALYSIS MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 121 TABLE 61 EUROPE: RNA ANALYSIS MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 122 TABLE 62 ASIA PACIFIC: RNA ANALYSIS MARKET FOR COMPARATIVE TRANSCRIPTOMICS, BY COUNTRY, 2021–2028 (USD MILLION) 122 9 RNA ANALYSIS MARKET, BY END USER 123 9.1 INTRODUCTION 124 TABLE 63 RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 124 9.2 PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES 124 9.2.1 INCREASING INVESTMENTS FOR ONCOLOGY THERAPEUTICS TO DRIVE USE OF OMICS TECHNOLOGIES IN PHARMA & BIOTECH COMPANIES 124 TABLE 64 RNA ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2021–2028 (USD MILLION) 125 TABLE 65 NORTH AMERICA: RNA ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 126 TABLE 66 EUROPE: RNA ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 126 TABLE 67 ASIA PACIFIC: RNA ANALYSIS MARKET FOR PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2021–2028 (USD MILLION) 127 9.3 HOSPITALS & DIAGNOSTIC CENTERS 127 9.3.1 USE OF WHOLE-BLOOD TRANSCRIPTOME PROFILES FOR DISEASE DIAGNOSTICS TO FAVOR MARKET GROWTH 127 TABLE 68 RNA ANALYSIS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2021–2028 (USD MILLION) 128 TABLE 69 NORTH AMERICA: RNA ANALYSIS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 128 TABLE 70 EUROPE: RNA ANALYSIS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 129 TABLE 71 ASIA PACIFIC: RNA ANALYSIS MARKET FOR HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2021–2028 (USD MILLION) 129 9.4 ACADEMIC & RESEARCH INSTITUTES 130 9.4.1 GROWING GOVERNMENT INVESTMENTS TO PROPEL MARKET GROWTH 130 TABLE 72 RNA ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2021–2028 (USD MILLION) 130 TABLE 73 NORTH AMERICA: RNA ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 131 TABLE 74 EUROPE: RNA ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 131 TABLE 75 ASIA PACIFIC: RNA ANALYSIS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2021–2028 (USD MILLION) 132 9.5 CONTRACT RESEARCH ORGANIZATIONS 132 9.5.1 GROWING OUTSOURCING OF SERVICES BY PHARMACEUTICAL COMPANIES FOR FASTER DRUG DISCOVERY TO AID MARKET GROWTH 132 TABLE 76 RNA ANALYSIS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2021–2028 (USD MILLION) 133 TABLE 77 NORTH AMERICA: RNA ANALYSIS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 133 TABLE 78 EUROPE: RNA ANALYSIS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 134 TABLE 79 ASIA PACIFIC: RNA ANALYSIS MARKET FOR CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2021–2028 (USD MILLION) 134 10 RNA ANALYSIS MARKET, BY REGION 135 10.1 INTRODUCTION 136 TABLE 80 RNA ANALYSIS MARKET, BY REGION, 2021–2028 (USD MILLION) 136 10.2 NORTH AMERICA 137 FIGURE 30 NORTH AMERICA: RNA ANALYSIS MARKET SNAPSHOT 138 TABLE 81 NORTH AMERICA: RNA ANALYSIS MARKET, BY COUNTRY, 2021–2028(USD MILLION) 139 TABLE 82 NORTH AMERICA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 139 TABLE 83 NORTH AMERICA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 140 TABLE 84 NORTH AMERICA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 140 TABLE 85 NORTH AMERICA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 141 10.2.1 US 141 10.2.1.1 US to dominate North American RNA analysis market during forecast period 141 TABLE 86 US: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 142 TABLE 87 US: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 143 TABLE 88 US: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 143 TABLE 89 US: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 144 10.2.2 CANADA 144 10.2.2.1 Improving funding and infrastructure for omics-based research to support market growth 144 TABLE 90 CANADA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 145 TABLE 91 CANADA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 146 TABLE 92 CANADA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 146 TABLE 93 CANADA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 147 10.2.3 NORTH AMERICA: RECESSION IMPACT 147 10.3 EUROPE 147 TABLE 94 EUROPE: RNA ANALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 148 TABLE 95 EUROPE: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 149 TABLE 96 EUROPE: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 149 TABLE 97 EUROPE: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 150 TABLE 98 EUROPE: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 150 10.3.1 GERMANY 151 10.3.1.1 Germany to hold largest share of European RNA analysis market during forecast period 151 TABLE 99 GERMANY: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 152 TABLE 100 GERMANY: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 152 TABLE 101 GERMANY: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 153 TABLE 102 GERMANY: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 153 10.3.2 UK 154 10.3.2.1 Rising public and private funding for research to drive market growth 154 TABLE 103 UK: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 154 TABLE 104 UK: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 155 TABLE 105 UK: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 155 TABLE 106 UK: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 156 10.3.3 FRANCE 156 10.3.3.1 Increasing government support for omics-based research to support market growth 156 TABLE 107 FRANCE: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 157 TABLE 108 FRANCE: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 157 TABLE 109 FRANCE: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 158 TABLE 110 FRANCE: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 158 10.3.4 ITALY 159 10.3.4.1 Improving R&D expenditure and disease diagnostics to boost market 159 TABLE 111 ITALY: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 159 TABLE 112 ITALY: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 160 TABLE 113 ITALY: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 160 TABLE 114 ITALY: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 161 10.3.5 SPAIN 161 10.3.5.1 Increasing collaborations for enhancing research to support market growth 161 TABLE 115 SPAIN: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 162 TABLE 116 SPAIN: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 162 TABLE 117 SPAIN: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 163 TABLE 118 SPAIN: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 163 10.3.6 SWITZERLAND 164 10.3.6.1 Well-established pharmaceutical industry to drive market growth 164 TABLE 119 SWITZERLAND: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 164 TABLE 120 SWITZERLAND: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 165 TABLE 121 SWITZERLAND: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 165 TABLE 122 SWITZERLAND: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 166 10.3.7 REST OF EUROPE 166 TABLE 123 REST OF EUROPE: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 167 TABLE 124 REST OF EUROPE: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 167 TABLE 125 REST OF EUROPE: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 168 TABLE 126 REST OF EUROPE: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 168 10.4 EUROPE: RECESSION IMPACT 169 10.5 ASIA PACIFIC 169 FIGURE 31 ASIA PACIFIC: RNA ANALYSIS MARKET SNAPSHOT 170 TABLE 127 ASIA PACIFIC: RNA ANALYSIS MARKET, BY COUNTRY, 2021–2028 (USD MILLION) 171 TABLE 128 ASIA PACIFIC: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 171 TABLE 129 ASIA PACIFIC: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 172 TABLE 130 ASIA PACIFIC: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 172 TABLE 131 ASIA PACIFIC: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 173 10.5.1 CHINA 173 10.5.1.1 China to be fastest-growing market in Asia Pacific during forecast period 173 TABLE 132 CHINA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 174 TABLE 133 CHINA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 175 TABLE 134 CHINA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 175 TABLE 135 CHINA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 176 10.5.2 JAPAN 176 10.5.2.1 Early adoption of technologically advanced products to drive market growth 176 TABLE 136 JAPAN: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 177 TABLE 137 JAPAN: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 177 TABLE 138 JAPAN: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 178 TABLE 139 JAPAN: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 178 10.5.3 INDIA 179 10.5.3.1 Increasing pharmaceutical R&D spending and government funding for research to drive market growth 179 TABLE 140 INDIA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 180 TABLE 141 INDIA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 180 TABLE 142 INDIA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 181 TABLE 143 INDIA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 181 10.5.4 REST OF ASIA PACIFIC 182 TABLE 144 REST OF ASIA PACIFIC: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 183 TABLE 145 REST OF ASIA PACIFIC: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 183 TABLE 146 REST OF ASIA PACIFIC: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 184 TABLE 147 REST OF ASIA PACIFIC: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 184 10.6 ASIA PACIFIC: RECESSION IMPACT 185 10.7 LATIN AMERICA 185 10.7.1 GROWTH IN PHARMACEUTICAL INDUSTRY IN MEXICO TO SUPPORT MARKET GROWTH 185 TABLE 148 LATIN AMERICA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 186 TABLE 149 LATIN AMERICA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 186 TABLE 150 LATIN AMERICA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 187 TABLE 151 LATIN AMERICA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 187 10.8 LATIN AMERICA: RECESSION IMPACT 188 10.9 MIDDLE EAST & AFRICA 188 10.9.1 IMPROVING FOCUS ON PRECISION MEDICINE AND DISEASE GENETICS TO DRIVE MARKET GROWTH 188 TABLE 152 MIDDLE EAST & AFRICA: RNA ANALYSIS MARKET, BY PRODUCT & SERVICE, 2021–2028 (USD MILLION) 189 TABLE 153 MIDDLE EAST & AFRICA: RNA ANALYSIS MARKET, BY TECHNOLOGY, 2021–2028 (USD MILLION) 189 TABLE 154 MIDDLE EAST & AFRICA: RNA ANALYSIS MARKET, BY APPLICATION, 2021–2028 (USD MILLION) 190 TABLE 155 MIDDLE EAST & AFRICA: RNA ANALYSIS MARKET, BY END USER, 2021–2028 (USD MILLION) 190 10.10 MIDDLE EAST & AFRICA: RECESSION IMPACT 191 11 COMPETITIVE LANDSCAPE 192 11.1 INTRODUCTION 192 11.2 STRATEGIES ADOPTED BY KEY PLAYERS 192 FIGURE 32 RNA ANALYSIS MARKET: STRATEGIES ADOPTED BY KEY PLAYERS 193 11.3 REVENUE SHARE ANALYSIS 194 FIGURE 33 REVENUE ANALYSIS OF KEY PLAYERS, 2020–2022 194 11.4 MARKET SHARE ANALYSIS 194 FIGURE 34 MARKET SHARE ANALYSIS OF KEY PLAYERS, 2022 195 TABLE 156 RNA ANALYSIS MARKET: DEGREE OF COMPETITION 195 11.5 COMPANY EVALUATION QUADRANT: KEY PLAYERS 196 FIGURE 35 RNA ANALYSIS MARKET: COMPANY EVALUATION MATRIX FOR KEY PLAYERS, 2022 197 11.5.1 STARS 197 11.5.2 EMERGING LEADERS 197 11.5.3 PERVASIVE PLAYERS 198 11.5.4 PARTICIPANTS 198 11.6 COMPETITIVE BENCHMARKING OF TOP 25 PLAYERS 198 11.6.1 COMPANY PRODUCT FOOTPRINT OF COMPANIES (25 COMPANIES) 198 TABLE 157 COMPANY PRODUCT FOOTPRINT ANALYSIS OF KEY PLAYERS IN RNA ANALYSIS MARKET 198 11.6.2 REGIONAL FOOTPRINT OF COMPANIES (25 COMPANIES) 199 TABLE 158 REGIONAL FOOTPRINT ANALYSIS OF KEY PLAYERS IN RNA ANALYSIS MARKET 199 11.7 COMPANY EVALUATION QUADRANT: STARTUPS/SMES 200 FIGURE 36 RNA ANALYSIS MARKET: COMPANY EVALUATION MATRIX FOR STARTUPS/ SMES, 2022 200 11.7.1 PROGRESSIVE COMPANIES 201 11.7.2 STARTING BLOCKS 201 11.7.3 RESPONSIVE COMPANIES 201 11.7.4 DYNAMIC COMPANIES 201 11.8 COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 202 TABLE 159 RNA ANALYSIS MARKET: DETAILED LIST OF KEY STARTUP/SME PLAYERS 202 TABLE 160 RNA ANALYSIS MARKET: COMPETITIVE BENCHMARKING OF STARTUP/SME PLAYERS 203 11.9 COMPETITIVE SCENARIO AND TRENDS 203 11.9.1 PRODUCT LAUNCHES 203 TABLE 161 RNA ANALYSIS MARKET: PRODUCT & SERVICE LAUNCHES, JANUARY 2020–JUNE 2023 203 11.9.2 DEALS 204 TABLE 162 RNA ANALYSIS MARKET: DEALS, JANUARY 2020–JUNE 2023 204 11.9.3 OTHER DEVELOPMENTS 205 TABLE 163 RNA ANALYSIS MARKET: OTHER DEVELOPMENTS, JANUARY 2020–JUNE 2023 205 12 COMPANY PROFILES 206 12.1 KEY PLAYERS 206 (Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 12.1.1 THERMO FISHER SCIENTIFIC INC. 206 TABLE 164 THERMO FISHER SCIENTIFIC INC.: BUSINESS OVERVIEW 206 FIGURE 37 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2022) 207 12.1.2 F. HOFFMANN-LA ROCHE LTD. 212 TABLE 165 F. HOFFMANN-LA ROCHE LTD.: BUSINESS OVERVIEW 212 FIGURE 38 F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2022) 213 12.1.3 BIO-RAD LABORATORIES, INC. 216 TABLE 166 BIO-RAD LABORATORIES, INC.: COMPANY OVERVIEW 216 FIGURE 39 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2022) 217 12.1.4 ILLUMINA, INC. 220 TABLE 167 ILLUMINA, INC.: COMPANY OVERVIEW 220 FIGURE 40 ILLUMINA, INC.: COMPANY SNAPSHOT (2022) 221 12.1.5 EUROFINS SCIENTIFIC 224 TABLE 168 EUROFINS SCIENTIFIC: COMPANY OVERVIEW 224 FIGURE 41 EUROFINS SCIENTIFIC: COMPANY SNAPSHOT (2022) 224 12.1.6 AGILENT TECHNOLOGIES, INC. 227 TABLE 169 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW 227 FIGURE 42 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2022) 228 12.1.7 CD GENOMICS 230 TABLE 170 CD GENOMICS: COMPANY OVERVIEW 230 12.1.8 PROMEGA CORPORATION 232 TABLE 171 PROMEGA CORPORATION: COMPANY OVERVIEW 232 12.1.9 QIAGEN N.V. 234 TABLE 172 QIAGEN N.V.: COMPANY OVERVIEW 234 FIGURE 43 QIAGEN N.V.: COMPANY SNAPSHOT (2022) 235 12.1.10 DANAHER CORPORATION 237 TABLE 173 DANAHER CORPORATION: COMPANY OVERVIEW 237 FIGURE 44 DANAHER CORPORATION: COMPANY SNAPSHOT (2022) 238 12.1.11 MERCK KGAA 240 TABLE 174 MERCK KGAA: BUSINESS OVERVIEW 240 FIGURE 45 MERCK KGAA: COMPANY SNAPSHOT (2022) 241 12.1.12 STANDARD BIOTOOLS INC. (FLUIDIGM CORPORATION) 243 TABLE 175 STANDARD BIOTOOLS INC.: BUSINESS OVERVIEW 243 FIGURE 46 STANDARD BIOTOOLS INC.: COMPANY SNAPSHOT (2022) 243 12.1.13 SEQUENTIA BIOTECH SL 245 TABLE 176 SEQUENTIA BIOTECH SL: BUSINESS OVERVIEW 245 12.1.14 ACOBIOM 246 TABLE 177 ACOBIOM: BUSINESS OVERVIEW 246 12.1.15 GENXPRO GMBH 247 TABLE 178 GENXPRO GMBH: BUSINESS OVERVIEW 247 12.2 OTHER PLAYERS 248 12.2.1 LEXOGEN GMBH 248 12.2.2 CENIX BIOSCIENCE GMBH 249 12.2.3 TAKARA HOLDINGS INC. 250 12.2.4 BIOMÉRIEUX SA 251 12.2.5 LC SCIENCES LLC 252 12.2.6 OXFORD NANOPORE TECHNOLOGIES 253 12.2.7 ZYMO RESEARCH CORPORATION 254 12.2.8 GENEDX 255 12.2.9 PARTEK INCORPORATED 255 12.2.10 BGI GROUP 256 *Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 13 APPENDIX 257 13.1 DISCUSSION GUIDE 257 13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 260 13.3 CUSTOMIZATION OPTIONS 262 13.4 RELATED REPORTS 262 13.5 AUTHOR DETAILS 263
ご注文は、お電話またはWEBから承ります。お見積もりの作成もお気軽にご相談ください。本レポートと同分野(バイオ薬物)の最新刊レポート
MarketsandMarkets社のBiotechnology分野での最新刊レポート
本レポートと同じKEY WORD(analysis market)の最新刊レポート
よくあるご質問MarketsandMarkets社はどのような調査会社ですか?マーケッツアンドマーケッツ(MarketsandMarkets)は通信、半導体、医療機器、エネルギーなど、幅広い市場に関する調査レポートを出版しています。また広範な市場を対象としたカスタム調査も行って... もっと見る 調査レポートの納品までの日数はどの程度ですか?在庫のあるものは速納となりますが、平均的には 3-4日と見て下さい。
注文の手続きはどのようになっていますか?1)お客様からの御問い合わせをいただきます。
お支払方法の方法はどのようになっていますか?納品と同時にデータリソース社よりお客様へ請求書(必要に応じて納品書も)を発送いたします。
データリソース社はどのような会社ですか?当社は、世界各国の主要調査会社・レポート出版社と提携し、世界各国の市場調査レポートや技術動向レポートなどを日本国内の企業・公官庁及び教育研究機関に提供しております。
|
詳細検索
2024/12/23 10:26 157.72 円 164.94 円 201.11 円 |